Cross-talk between macrophages and smooth muscle cells impairs collagen and metalloprotease synthesis and promotes angiogenesis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 7, 2016, Pages 1568-1578

  Butoi, E ^a   Gan, A M ^a,b   Tucureanu, M M ^a   Stan, D ^a   Macarie, R D ^a   Constantinescu, C ^a   Calin, M ^a   Simionescu, M ^a   Manduteanu, I ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^b NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Angiogenesis; Atherosclerosis; Extracellular matrix proteins; Macrophage SMC cross talk; Matrix metalloproteinases

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; ELASTIN; GELATINASE B; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; TOLL LIKE RECEPTOR 2; VASCULOTROPIN; AUTACOID; COLLAGEN; CONDITIONED MEDIUM; IL1B PROTEIN, HUMAN; MMP1 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL COMMUNICATION; CELLS BY BODY ANATOMY; COCULTURE; COLLAGEN SYNTHESIS; CONDITIONED MEDIUM; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME SYNTHESIS; FETUS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; SMOOTH MUSCLE CELL; UPREGULATION; ATHEROSCLEROSIS; CELL LINE; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CELL COMMUNICATION; CELL LINE; COCULTURE TECHNIQUES; COLLAGEN; CULTURE MEDIA, CONDITIONED; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MACROPHAGES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84964341248     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.04.001     Document Type: Article

References (60)

1. Finn A.V., Nakano M., Narula J., Kolodgie F.D., Virmani R. Concept of vulnerable/unstable plaque. Arterioscler. Thromb. Vasc. Biol. Jul. 2010, 30(7):1282-1292.
2. Lee R.T., Libby P. The unstable atheroma. Arterioscler. Thromb. Vasc. Biol. Oct. 1997, 17(10):1859-1867.
3. Adiguzel E., Ahmad P.J., Franco C., Bendeck M.P. Collagens in the progression and complications of atherosclerosis. Vasc. Med. Feb. 2009, 14(1):73-89.
4. Herman M.P., Sukhova G.K., Libby P., Gerdes N., Tang N., Horton D.B., Kilbride M., Breitbart R.E., Chun M., Schönbeck U. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation Oct. 2001, 104(16):1899-1904.
5. Varani J., Perone P., Fligiel S.E.G., Fisher G.J., Voorhees J.J. Inhibition of type I procollagen production in photodamage: correlation between presence of high molecular weight collagen fragments and reduced procollagen synthesis. J. Investig. Dermatol. Jul. 2002, 119(1):122-129.
6. Murillo C.A., Woodside K.J., Guo Q., Zhang S., O'Connor K.L., Hunter G.C. Integrin and matrix metalloproteinase expression in human carotid plaque. J. Surg. Res. Jul. 2009, 155(1):157-164.
7. Quillard T., Tesmenitsky Y., Croce K., Travers R., Shvartz E., Koskinas K.C., Sukhova G.K., Aikawa E., Aikawa M., Libby P. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler. Thromb. Vasc. Biol. Nov. 2011, 31(11):2464-2472.
8. Lacolley P., Regnault V., Nicoletti A., Li Z., Michel J.-B. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc. Res. Jul. 2012, 95(2):194-204.
9. Moulton K.S., Vakili K., Zurakowski D., Soliman M., Butterfield C., Sylvin E., Lo K.-M., Gillies S., Javaherian K., Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. Apr. 2003, 100(8):4736-4741.
10. Chistiakov D.A., Orekhov A.N., Bobryshev Y.V. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol (Oxf.) Mar. 2015, 213(3):539-553.
11. Michel J.-B., Virmani R., Arbustini E., Pasterkamp G. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur. Heart J. Aug. 2011, 32(16). pp. 1977-1985, 1985a, 1985b, 1985c.
12. Ho-Tin-Noé B., Le Dall J., Gomez D., Louedec L., Vranckx R., El-Bouchtaoui M., Legrès L., Meilhac O., Michel J.-B. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-γ trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ. Res. Oct. 2011, 109(9):1003-1014.
13. Li Z., Li Y., Lin M., Su W., Zhang W.-X., Zhang Y., Yao L., Liang D. Activated macrophages induce neovascularization through upregulation of MMP-9 and VEGF in rat corneas. Cornea Sep. 2012, 31(9):1028-1035.
14. Carmi Y., Voronov E., Dotan S., Lahat N., Rahat M.A., Fogel M., Huszar M., White M.R., Dinarello C.A., Apte R.N. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. Oct. 2009, 183(7):4705-4714.
15. Cho M.-L., Ju J.-H., Kim H.-R., Oh H.-J., Kang C.-M., Jhun J.-Y., Lee S.-Y., Park M.-K., Min J.-K., Park S.-H., Lee S.-H., Kim H.-Y. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunol. Lett. Feb. 2007, 108(2):121-128.
16. Monaco C., Gregan S.M., Navin T.J., Foxwell B.M.J., Davies A.H., Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation Dec. 2009, 120(24):2462-2469.
17. Butoi E.D., Gan A.M., Manduteanu I., Stan D., Calin M., Pirvulescu M., Koenen R.R., Weber C., Simionescu M. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim. Biophys. Acta Dec. 2011, 1813(12):2026-2035.
18. Li P., Li Y., Li Z., Wu Y., Zhang C., A X., Wang C., Shi H., Hui M., Xie B., Ahmed M., Du J. Cross talk between vascular smooth muscle cells and monocytes through interleukin-1β/interleukin-18 signaling promotes vein graft thickening. Arterioscler. Thromb. Vasc. Biol. Sep. 2014, 34(9):2001-2011.
19. Chen L., Frister A., Wang S., Ludwig A., Behr H., Pippig S., Li B., Simm A., Hofmann B., Pilowski C., Koch S., Buerke M., Rose-John S., Werdan K., Loppnow H. Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. Am. J. Physiol. Heart Circ. Physiol. Apr. 2009, 296(4):H987-H996.
20. Tîrziu D., Jinga V.V., Serban G., Simionescu M. The effects of low density lipoproteins modified by incubation with chondroitin 6-sulfate on human aortic smooth muscle cells. Atherosclerosis Nov. 1999, 147(1):155-166.
21. Raicu M., Florea S. Deleterious effects of nifedipine on smooth muscle cells implies alterations of intracellular calcium signaling. Fundam. Clin. Pharmacol. Dec. 2001, 15(6):387-392.
22. Dragomir E., Manduteanu I., Calin M., Gan A.M., Stan D., Koenen R.R., Weber C., Simionescu M. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb. Haemost. Dec. 2008, 100(6):1155-1165.
23. World medical association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc. Res. Jul. 1997, 35(1):2-3.
24. Chanput W., Mes J.J., Savelkoul H.F.J., Wichers H.J. Characterization of polarized THP-1 macrophages and polarizing ability of LPS and food compounds. Food Funct. Feb. 2013, 4(2):266-276.
25. Daigneault M., Preston J.A., Marriott H.M., Whyte M.K.B., Dockrell D.H. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 2010, 5(1):e8668.
26. Schnoor M., Cullen P., Lorkowski J., Stolle K., Robenek H., Troyer D., Rauterberg J., Lorkowski S. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J. Immunol. Apr. 2008, 180(8):5707-5719.
27. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. Feb. 2006, 69(3):562-573.
28. Stupack D.G., Cheresh D.A. ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci. STKE Feb. 2002, 2002(119):pe7.
29. Song X., Voronov E., Dvorkin T., Fima E., Cagnano E., Benharroch D., Shendler Y., Bjorkdahl O., Segal S., Dinarello C.A., Apte R.N. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J. Immunol. Dec. 2003, 171(12):6448-6456.
30. Nakao S., Kuwano T., Tsutsumi-Miyahara C., Ueda S., Kimura Y.N., Hamano S., Sonoda K., Saijo Y., Nukiwa T., Strieter R.M., Ishibashi T., Kuwano M., Ono M. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J. Clin. Invest. Nov. 2005, 115(11):2979-2991.
31. Carmi Y., Dotan S., Rider P., Kaplanov I., White M.R., Baron R., Abutbul S., Huszar M., Dinarello C.A., Apte R.N., Voronov E. The role of IL-1β in the early tumor cell-induced angiogenic response. J. Immunol. Apr. 2013, 190(7):3500-3509.
32. Curtiss L.K., Tobias P.S. Emerging role of toll-like receptors in atherosclerosis. J. Lipid Res. Apr. 2009, 50:S340-S345. (Suppl.).
33. Lee J.H., Joo J.H., Kim J., Lim H.J., Kim S., Curtiss L., Seong J.K., Cui W., Yabe-Nishimura C., Bae Y.S. Interaction of NADPH oxidase 1 with toll-like receptor 2 induces migration of smooth muscle cells. Cardiovasc. Res. Aug. 2013, 99(3):483-493.
34. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell Aug. 2002, 10(2):417-426.
35. Manduteanu I., Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders?. J. Cell. Mol. Med. Sep. 2012, 16(9):1978-1990.
36. Xia J., Wu X., Yang Y., Zhao Y., Fang M., Xie W., Wang H., Xu Y. SIRT1 deacetylates RFX5 and antagonizes repression of collagen type I (COL1A2) transcription in smooth muscle cells. Biochem. Biophys. Res. Commun. Nov. 2012, 428(2):264-270.
37. Shah P.K. Inflammation and plaque vulnerability. Cardiovasc. Drugs Ther. Feb. 2009, 23(1):31-40.
38. Rao V.H., Kansal V., Stoupa S., Agrawal D.K. MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Phys. Rep. Feb. 2014, 2(2):e00224.
39. Libby P. Collagenases and cracks in the plaque. J. Clin. Invest. Aug. 2013, 123(8):3201-3203.
40. Luttun A., Lutgens E., Manderveld A., Maris K., Collen D., Carmeliet P., Moons L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation Mar. 2004, 109(11):1408-1414.
41. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
42. Newby A.C., George S.J., Ismail Y., Johnson J.L., Sala-Newby G.B., Thomas A.C. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb. Haemost. Jun. 2009, 101(6):1006-1011.
43. Guo L., Ning W., Tan Z., Gong Z., Li X. Mechanism of matrix metalloproteinase axis-induced neointimal growth. J. Mol. Cell. Cardiol. Jan. 2014, 66:116-125.
44. Johnson J.L., George S.J., Newby A.C., Jackson C.L. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl. Acad. Sci. U. S. A. Oct. 2005, 102(43):15575-15580.
45. Heo S.H., Cho C.-H., Kim H.O., Jo Y.H., Yoon K.-S., Lee J.H., Park J.-C., Park K.C., Ahn T.-B., Chung K.C., Yoon S.-S., Chang D.-I. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J. Clin. Neurol. Jun. 2011, 7(2):69-76.
46. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R., Thompson M.M. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke Jan. 2000, 31(1):40-47.
47. Sluijter J.P.G., Pulskens W.P.C., Schoneveld A.H., Velema E., Strijder C.F., Moll F., de Vries J.-P., Verheijen J., Hanemaaijer R., de Kleijn D.P.V., Pasterkamp G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke Jan. 2006, 37(1):235-239.
48. Ferroni P., Basili S., Martini F., Cardarello C.M., Ceci F., Di Franco M., Bertazzoni G., Gazzaniga P.P., Alessandri C. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J. Investig. Med. Sep. 2003, 51(5):295-300.
49. Preston G.A., Barrett C.V., Alcorta D.A., Hogan S.L., Dinwiddie L., Jennette J.C., Falk R.J. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron Dec. 2002, 92(4):817-823.
50. Rabkin S.W. Differential expression of MMP-2, MMP-9 and TIMP proteins in thoracic aortic aneurysm - comparison with and without bicuspid aortic valve: a meta-analysis. Vasa Nov. 2014, 43(6):433-442.
51. Piccardi B., Palumbo V., Nesi M., Nencini P., Gori A.M., Giusti B., Pracucci G., Tonelli P., Innocenti E., Sereni A., Sticchi E., Toni D., Bovi P., Guidotti M., Tola M.R., Consoli D., Micieli G., Tassi R., Orlandi G., Perini F., Marcello N., Nucera A., Massaro F., DeLodovici M.L., Bono G., Sessa M., Abbate R., Inzitari D. Unbalanced metalloproteinase-9 and tissue inhibitors of metalloproteinases ratios predict hemorrhagic transformation of lesion in ischemic stroke patients treated with thrombolysis: results from the MAGIC study. Front. Neurol. 2015, 6:121.
52. Johnson J.L., Baker A.H., Oka K., Chan L., Newby A.C., Jackson C.L., George S.J. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation May 2006, 113(20):2435-2444.
53. Jadhav U., Chigurupati S., Lakka S.S., Mohanam S. Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int. J. Oncol. Nov. 2004, 25(5):1407-1414.
54. Cai Q., Lanting L., Natarajan R. Interaction of monocytes with vascular smooth muscle cells regulates monocyte survival and differentiation through distinct pathways. Arterioscler. Thromb. Vasc. Biol. Dec. 2004, 24(12):2263-2270.
55. Rao V.H., Rai V., Stoupa S., Agrawal D.K. Blockade of Ets-1 attenuates epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. Sep. 2015, 309(6):H1075-H1086.
56. Albasanz-Puig A., Murray J., Namekata M., Wijelath E.S. Opposing roles of STAT-1 and STAT-3 in regulating vascular endothelial growth factor expression in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. Nov. 2012, 428(1):179-184.
57. Snodgrass R.G., Huang S., Choi I.-W., Rutledge J.C., Hwang D.H. Inflammasome-mediated secretion of IL-1β in human monocytes through TLR2 activation; modulation by dietary fatty acids. J. Immunol. Oct. 2013, 191(8):4337-4347.
58. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. Oct. 2010, 277(19):3864-3875.
59. Aplin A.C., Ligresti G., Fogel E., Zorzi P., Smith K., Nicosia R.F. Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by toll-like receptors. Angiogenesis Jan. 2014, 17(1):147-161.
60. Zhong Z.X., Li B., Li C.R., Zhang Q.F., Liu Z.D., Zhang P.F., Gu X.F., Luo H., Li M.J., Luo H.S., Ye G.H., Wen F.L. Role of chemokines in promoting instability of coronary atherosclerotic plaques and the underlying molecular mechanism. Braz. J. Med. Biol. Res. Feb. 2015, 48(2):161-166.